Expression and clinical significance of ARHI and p130 in endometrial carcinoma

Background: To evaluate the expression status of ARHI protein and pRb2/p130 in endometrial cancer (EC), while analyzing the relevance in EC simultaneously. Materials and Methods: Surgical resection of 20 tumor samples from primary EC patients, 20 atypical hyperplasia endometrial samples, and ten normal endometrial samples from benign disease such as uterine fibroid after surgery were randomly chosen for co-immunoprecipitation assays, which was used to explore the expression of ARHI and p130. Results: The positive status of ARHI protein in dropped gradually from normal endometrial tissues at proliferative stage (90%), endometrial tissues of atypical hyperplasia (50%) to EC tissues (30%); statistically significant differences were evaluated among the groups (p < 0.05). Meanwhile The positive rate of pRb2/p130 decreased gradually, which had a apparent difference among groups (p < 0.05). There were correlations between lack of positive statue of ARHI and the degree of EC and clinicopathological classification (p < 0.05). However the positive expression statue of ARHI protein was not associated with the histological type (p > 0.05). However, there were correlations between lack of positive expression of pRb2/p130 and the degree of EC, classification of surgical pathology, and histological type (p < 0.05). Conclusions: The drop or lack of the positive expression status of ARHI protein and pRb2/P130 result in the occurrence and worsening of EC.

ARHI; p130; Immunohistochemical; Endometrial carcinoma; Endometrial cancer.

[1] Peng W.X., Kudo M., Fujii T., Teduka K., Naito Z: “Altered expression of fibroblast growth factor receptor 2 isoform IIIc: relevance to endometrioid adenocarcinoma carcinogenesis and histological differentiation”. Int. J. Clin. Exp. Pathol., 2014, 7, 1069.

[2] Li J., Cui G., Sun L., Wang S.J., Tian S., Guan Z., et al.: “ARHI Over-expression Induces Epithelial Ovarian Cancer Cell Apoptosis and Excessive Autophagy”. Gynecol. Cancer, 2014, 11, 437.

[3] Shen W.J, Xing F.Q., Lu Y.X: “The expression of imprinted tumor suppressor gene ARHI and DNA Methylation of ARHI in Serous ovarian cancer”. PLA(Peoples Liberation Army) Medicine, 2013, 33, 302.

[4] Yu Y., Luo R., Lu Z., Wei F.W., Badgwell D., Issa J.P., et al.: “Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers”. Methods Enzymol., 2006, 40, 455.

[5] Yang H., Lu X., Qian J., Xu F., Hu Y., Yu Y., et al.: “Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells”. Mol. Med. Rep., 2010, 11, 581.

[6] Frusta S., Hidaka E., Ogata A: “RAS is involved in the negative control of autophagy through the class PI3K-kinase”. Oncol. Rep.,2004, 23, 898.

[7] Yu Y., Fujii S., Yuan J., Luo R.Z., Wang L., Bao J., et al.: “Epigenetic regulation of ARHI in breast and ovarian cancer cells”. Ann. N. Y. Acad. Sci.,2003, 9, 268.

[8] Luo R.Z., Peng H., Xu F., Bao J., Pang Y., Pershad R., et al.: “Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI”. Biochim. Biophys. Acta., 2010, 1519, 216.

[9] Melcher R., Hartmann E., Zopf W., Herterich S., Wilke P., Müller L., et al.: “LOH and copy neutral LOH act as alternative mechanism in sporadic colorectal cancers with chromosomal and microsatellite instability”. Carcinogenesis, 2011, 32, 636.

[10] Lu Z., Luo R.Z., Peng H., Rosen D.G., Atkinson E.N., Warneke C., et al.: “Transcriptional and posttranscriptional down regulation of the imprinted tumor suppressor gene ARHI(DRAS3)in Ovarian Cancer”. Clin. Cancer Res, 2006, 12, 2404.

[11] Howard C.M., Claudio P.P., Gallia G.L., Gordon J., Giordano G.G., Hauck W.W., et al.: “Retinoblastoma-related protein pRb2/p130 and suppression of tumor growth in vivo”. J. Natl. Cancer Inst., 2013, 19, 233.

[12] Susini T., Massi D., Paglierani M., Masciullo V., Scambia G., Giordano A., et al.: “Expression of the retinoblastoma related gene Rb2/p130 is down-regulated in atypical endometrial hyperplasia and adenoid-carcinoma”. Human Heredity, 2001, 32, 360.

[13] Masciullo V., Berardengo E., Boglione A., Sgambato A., Bernardi A., Forni M., et al.: “The retinoblastoma family member pRb2/p130 is an independent predictor of survival in human soft tissue sarcomas”. Clin. Cancer Res., 2008, 14, 4775.

[14] Baldi A., Boccia V., Claudio P.P., De Luca A., Giordano A: “Genomic structure of the human retinoblastoma-related Rb2/p130 gene”. Proc. Nat. Acad. Sci. USA, 2010, 93, 629.

[15] Pertile P., Baldi A., De Luca A., Bagella L., Virgilio L., Pisano M.M., et al.: “Molecular Cloning Expression, and Developmental Characterization of the Murine Retinoblastoma-related Gene Rb2/p130”. Cell Growth Differ., 1995, 12, 1659.

[16] Fan Z.S., Ao S.Z: “The new progress of tumor suppressor genes RB and cell cycle regulation”. Progress. Biochem. Biophys., 2011, 26, 429.

[17] Liu J: “The action of REG in the molecular mechanisms regulating of the p53 protein ad the tumor formation”. Am. J. Med. Genetics, 2013, 13, 22.

[18] Morselli E., Tasdemir E., Maiuri M.C., Galluzzi L., Kepp O., Criollo A., et al.: “Mutant p53 protein localized in the cytoplasm inhibits autophagy”, Cell Cycle, 2008, 7, 3056.

[19] Zhang J., Cheng J.X: “The action and relationship of ARHI WWOX and PTEN factors in ovarian serous cancer”. J. Hebei Medical University, 2012, 20, 101.

[20] Sakai T., Toguchida J., Ohtani N., Yandell D.W., Rapaport J.M., Dryja T.P: “Allele specific hyper-methylation of the retinoblastoma tumor suppressor gene”. Hum. Genet., 2009, 24, 880.